Cancerous tumors are classified primarily based on their tissue of origin. However, the sequencing of the human genome and the development of powerful and affordable DNA sequencing technologies has ushered in a new era of precision oncology, in which patients are treated with customized therapies designed to target the specific mutations within their tumor.
This new treatment approach has yielded some important successes but, recently many cancers experts have begun to suspect that where a cancer arises in the body may influence how specific mutations behave, playing a major role in determining how patients respond to targeted treatments. Currently, the ways in which the tissue environment shapes the tumors genetic makeup are not well understood.
In a new paper, published in Nature, a team of researchers describe a new set of "rules" that predict how the tissue of origin influences critical aspects of the genetic makeup of tumors, with potentially important therapeutic implications.
Focusing on an essential cellular molecule called nicotinamide adenine dinucleotide (NAD), a critical co-factor required for many cellular reactions, including energy metabolism, epigenetic regulation and DNA damage response, the team identified a surprising role for tissue of origin in determining how cells make NAD, with important consequences for cancer treatment.
Normal cells make NAD by using any of three biochemical pathways. The team discovered that cancer cells behave in a very different way. By analyzing more than 7,000 tumors and 2,600 matched normal samples of 19 different tissue types, coupled with mathematical modelling and extensive studies in cells and in mice, the researchers found that where a cancer arises is the major determinant of how cancer cells make NAD.
In contrast to normal cells that can use any of the three pathways if needed, cancer cells can use only one NAD synthesis pathway, rendering them addicted to that pathway and highly vulnerable to targeted pharmacological intervention.
Specifically, in certain body organs, an enzyme called nicotinic acid phosphoribosyltransferease or NAPRT, a key regulator of one of the three pathways, is highly expressed. Cancers that arise from organs that highly express NAPRT include the prostate, ovaries, gastrointestinal tract and pancreatic tissues. They have a high frequency of NAPRT amplification and are completely and irreversibly dependent upon NAPRT for survival.'
The researchers showed that a drug that targets this pathway is very effective at killing tumors that arise from these organs, while sparing normal tissue, suggesting a promising new way to treat a large number of cancer patients. Tumors that arise from normal tissues that do not express NAPRT highly are entirely dependent on the NAD salvage pathway for survival.
Authors also identify the previously unknown enhancer that underlies this dependence. Amplification of NAPRT is shown to generate a pharmacologically actionable tumor cell dependence for survival. Dependence on another rate-limiting enzyme of the NAD synthesis pathway, NAMPT, as a result of enhancer remodelling is subject to resistance by NMRK1-dependent synthesis of NAD.
The study also demonstrate that cancers that don't arise from the organs mentioned become dependent on a different pathway for making NAD, via a change in epigenetic regulation, which indicates that patients who have these other types of cancer need to be treated with a different set of therapies targeting NAD metabolism.
"This work -- identifying and targeting cancer cell specific pathways of NAD metabolism in multiple different tumor types -- lays the groundwork for a new set of specific, selective and highly promising new cancer treatments that spare normal tissue," said the senior author.
https://ucsdnews.ucsd.edu/pressrelease/exposing_cancers_metabolic_addictions
https://www.nature.com/articles/s41586-019-1150-2
Latest News
Abusive drugs hijack natura…
By newseditor
Posted 23 Apr
Mechanism of action of the…
By newseditor
Posted 23 Apr
Role of fat in rare neurolo…
By newseditor
Posted 23 Apr
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Other Top Stories
'Jumping genes' drive many cancers
Read more
Gene duplications could be fixed with CRISPR/CAS9 and MMEJ repair m…
Read more
Normal mutations in human livers can promote tissue regeneration
Read more
Poverty leaves a mark on our genes
Read more
ALS progression at the genetic and cellular level
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Exploiting pancreatic cance…
By newseditor
Posted 23 Apr
Structure of antiviral drug…
By newseditor
Posted 23 Apr
Type-I-interferon-responsiv…
By newseditor
Posted 23 Apr
Selenium, diabetes, and the…
By newseditor
Posted 23 Apr
Long-term neuropsychologica…
By newseditor
Posted 23 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar